152 related articles for article (PubMed ID: 10357418)
1. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
3. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
4. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Cheng L; Pisansky TM; Sebo TJ; Leibovich BC; Ramnani DM; Weaver AL; Scherer BG; Blute ML; Zincke H; Bostwick DG
Clin Cancer Res; 1999 Oct; 5(10):2820-3. PubMed ID: 10537347
[TBL] [Abstract][Full Text] [Related]
5. Dedifferentiation in the metastatic progression of prostate carcinoma.
Cheng L; Slezak J; Bergstralh EJ; Cheville JC; Sweat S; Zincke H; Bostwick DG
Cancer; 1999 Aug; 86(4):657-63. PubMed ID: 10440694
[TBL] [Abstract][Full Text] [Related]
6. Extranodal extension in lymph node-positive prostate cancer.
Cheng L; Pisansky TM; Ramnani DM; Leibovich BC; Cheville JC; Slezak J; Bergstralh EJ; Zincke H; Bostwick DG
Mod Pathol; 2000 Feb; 13(2):113-8. PubMed ID: 10697266
[TBL] [Abstract][Full Text] [Related]
7. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
9. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
10. P53 expression in squamous cell carcinomas of the supraglottic larynx and its lymph node metastases: new results for an old question.
Cabanillas R; Rodrigo JP; Astudillo A; Domínguez F; Suárez C; Chiara MD
Cancer; 2007 May; 109(9):1791-8. PubMed ID: 17380529
[TBL] [Abstract][Full Text] [Related]
11. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
13. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
15. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
[TBL] [Abstract][Full Text] [Related]
16. Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer.
Leibovich BC; Cheng L; Weaver AL; Myers RP; Bostwick DG
J Urol; 2000 Jun; 163(6):1756-60. PubMed ID: 10799176
[TBL] [Abstract][Full Text] [Related]
17. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Bader P; Burkhard FC; Markwalder R; Studer UE
J Urol; 2003 Mar; 169(3):849-54. PubMed ID: 12576797
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
19. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
